ReviewJournal of investigative medicine high impact case reports
Subacute Coronary Stent Thrombosis as the Initial Presentation of Acute Myeloid Leukemia: A Case Report and Literature Review.
Review in Journal of investigative medicine high impact case reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Subacute stent thrombosis is an uncommon but life-threatening complication of percutaneous coronary intervention (PCI). While mechanical and antiplatelet-related factors are most frequently implicated, systemic hypercoagulable conditions are increasingly recognized as important contributors. Acute myeloid leukemia (AML) is associated with complex hemostatic abnormalities that may predispose to both venous and arterial thrombosis, particularly in the presence of hyperleukocytosis. We report the case of a 33-year-old male with minimal cardiovascular risk factors who presented with ST-segment elevation myocardial infarction and was found to have a large thrombus burden in the proximal left anterior descending artery. Despite pharmacologic reperfusion and subsequent drug-eluting stent implantation, he re-presented ten days after discharge with subacute stent thrombosis and additional thrombotic involvement of multiple coronary vessels, leading to hemodynamic instability. Although he reported adherence to dual antiplatelet therapy, laboratory evaluation revealed rapidly progressive leukocytosis accompanied by anemia and thrombocytopenia. Further hematologic workup confirmed a diagnosis of acute myeloid leukemia with profound hyperleukocytosis. Cytoreductive therapy was initiated, but the course was complicated by tumor lysis syndrome and acute kidney injury, necessitating renal replacement therapy prior to transfer for definitive oncologic management. This case highlights AML-associated hypercoagulability and hyperleukocytosis as potential contributors to early and recurrent coronary thrombosis following PCI. Leukostasis, endothelial activation, and blast-mediated procoagulant activity likely acted synergistically with stent-related endothelial injury to promote thrombosis despite standard antiplatelet therapy. Early or recurrent stent thrombosis, particularly in younger patients or in the presence of unexplained hematologic abnormalities, should prompt evaluation for underlying malignancy. Recognition of AML in this context is critical, as it may influence revascularization strategy, antithrombotic management, and overall prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.